Cortisol production rate is increased but peak plasma cortisol is paradoxically lower in obesity, suggesting that cortisol metabolism may be enhanced and this could drive activation of the hypothalamic ± pituitary ± adrenal (HPA) axis.
Subjects 31 men and 37 post-menopausal women (47 ± 53 y), with equal representation across the range of insulin sensitivity. The men were signi®cantly taller (1.71 AE 0.07 vs 1.57 AE 0.06 m, P`0.0001) and heavier (77.4 AE 9.8 vs 62.4 AE 9.5 kg, P`0.0001) than the women, with larger abdominal girth (93AE 8 vs 79AE 11 cm, P`0.0001) but equivalent hip girth (100AE 6 vs 98 AE 7 cm, P 0.29) and body mass index (26.6 AE 3.4 vs 25.2AE 4.1 kgam 2 , P 0.12). nine women were receiving oestrogen replacement therapy.
Measurements
24 h urine samples were collected and cortisol and its metabolites measured by gas chromatography mass spectrometry. Regression analyses and Student's ttests were performed to identify correlations between cortisol metabolism and indices of obesity and the in¯uence of gender.
Results
Indices of obesity were not correlated with total cortisol metabolite excretion; however, increased abdominal and hip circumferences were associated with lower 5ba5a reduced metabolite ratio ( Figure 1 ). Increased ratios of reduced metabolites of cortisol vs that of cortisone (5a 5b-tetrahydrocortisolsa5b-tetrahydrocortisone) correlated with indices of obesity in men only (Figure 1 ). Women excreted less cortisol metabolites than men (6.9AE 3.4 vs 9.2 AE 5.5 mgad, P 0.04), displayed a lower 5ba5a reduced metabolite ratio than men (1.4 AE 0.5 vs 4.7 AE 0.5, P`0.001) and a higher ratio of reduced cortisol metabolites to those of cortisone (2.0 AE 0.9 vs 1.5 AE 0.7, P`0.001). None of these differences were confounded by oestrogen replacement therapy. The activity of 11bHSD 2 (urinary cortisolacortisone) was unaffected by obesity or gender.
Conclusions
Excretion of total cortisol metabolites was not increased in obesity in this study despite previous reports of the HPA axis being activated, although there was a trend in that direction. However, metabolism of cortisol by 5a-reductase was enhanced in obesity in both sexes, probably as a result of increased activity of the hepatic enzyme or by the increased mass of this enzyme present in additional adipose tissue. Adipose tissue also contains 11b-hydroxysteroid dehydrogenase type 1 (11bHSD1), the enzyme responsible for reactivating cortisone to cortisol 2 and the metabolite pro®les re¯ect an increase in the activity of this enzyme in men but not in women with obesity. This may be explained by data from the animal model of the Zucker obese rat which showed differential tissue speci®c metabolism of cortisol by this enzyme: bioactivity studies show the activity of 11bHSD1 was increased in adipose tissue, but reduced in the liver. 3 Thus in obesity, enhanced clearance of cortisol from the circulation by 5a-reductase may be responsible for lowering plasma cortisol and thus the increased drive to the HPA axis. However at the tissue level, 11bHSD1 may be enhanced causing increased local concentrations of cortisol. Elevated concentrations of cortisol promotes insulin resistance and lipogenesis. 4, 5 This mechanism may underpin the association between visceral obesity and insulin resistance in metabolic syndrome X, a condition bearing remarkable similarity to Cushing's syndrome.
